|SIGA Technologies, Inc.|
35 East 62nd Street
United States - Map
SIGA Technologies, Inc., a pharmaceutical company, engages in the development and commercialization of pharmaceutical solutions for smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. The companys lead product is Arestvyr, an orally administered antiviral drug that targets orthopoxviruses. It also has various drug series in the pre-clinical development stage against four serotypes of virus for dengue disease. In addition, the company develops anti-arenavirus drug for hemorrhagic fever arenaviruses comprising Lassa virus and sabia virus; other hemorrhagic fever viruses, including Rift Valley Fever, Lymphocytic choriomeningitis virus, and Ebola; and a broad spectrum antiviral candidate against viruses in the Poxviridae, Filoviridae, Bunyaviridae, Arenaviridae, Flaviviridae, Togaviridae, Retroviridae, and Picornaviridae families. SIGA Technologies, Inc. was founded in 1995 and is headquartered in New York, New York.
|SIGA Technologies, Inc.’s ISS Governance QuickScore as of May 1, 2013 is 10. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 1; Compensation: 10.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Eric A. Rose M.D.,
Exec. Chairman, Chief Exec. Officer and Member of National Biodefense Science Board
|Mr. Daniel J. Luckshire ,
Chief Financial Officer, Principal Accounting Officer, Exec. VP and Sec.
|Dr. Dennis E. Hruby Ph.D.,
Chief Scientific Officer and VP
|Mr. William J. Haynes II,
Exec. VP and Gen. Counsel
| Doris McCarthy ,
Director of Admin.
|Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|